MYGN Myriad Genetics Dashboard

Myriad Genetics Inc., is a leading genetic testing and precision medicine company dedicated to transforming patient lives worldwide. Myriad discovers and commercializes genetic tests that: determine the risk of developing disease, accurately diagnose disease, assess the risk of disease progression, and guide treatment decisions across medical specialties where molecular diagnostics can significantly improve patient care and lower healthcare costs.

Company profile

Ticker

MYGN

Exchange

NASDAQ

Website

www.myriad.com/

CEO

R. Bryan Riggsbee

Incorporated

Delaware

Location

Utah

Fiscal year end

Dec 31

Sector

Manufacturing > Pharmaceutical Preparation Manufacturing

Industry (SIC)

In Vitro & In Vivo Diagnostic Substances

Ortho Clinical Diagnostics • Idexx Laboratories • Quidel • Lantheus • Neogen • Meridian Bioscience • Celldex Therapeutics • Oxford Immunotec Global • Lucira Health • Intellia Therapeutics ...

SEC CIK

0000899923

Corporate docs

Articles of Incorporation & Bylaws

IRS number

870494517

MYGN stock data

S&P 500

1M 1Y 2Y 5Y

News

Pro users get this 30m faster

Benzinga's Top Ratings Upgrades, Downgrades For June 15, 2021

15 Jun 21

Raymond James Initiates Coverage On Myriad Genetics with Market Perform Rating

15 Jun 21

Raymond James analyst Andrew Cooper initiates coverage on Myriad Genetics (NASDAQ:MYGN) with a Market Perform rating.

Benzinga's Top Ratings Upgrades, Downgrades For June 3, 2021

3 Jun 21

Goldman Sachs Initiates Coverage On Myriad Genetics with Sell Rating, Announces Price Target of $25

3 Jun 21

Myriad Genetics to Sell its Myriad RBM to Q2 Solutions, Terms Not Disclosed

24 May 21

Press releases

Pro users get this 30m faster

Thomas P. Slavin, M.D., Named Chief Medical Officer for Myriad Genetics

16 Jun 21

SALT LAKE CITY, June 16, 2021 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in genetic testing and precision medicine, today announced that it has named Thomas P. Slavin Jr. (T.J.), M.D., FACMG,

Myriad Genetics CEO Paul J. Diaz to Present at Goldman Sachs 2021 Virtual Global Healthcare Conference

4 Jun 21

SALT LAKE CITY, June 04, 2021 (GLOBE NEWSWIRE) -- Paul J. Diaz, president and CEO of Myriad Genetics (NASDAQ:MYGN), a leader in genetic testing and precision medicine, will discuss the company's transformation plan and

Myriad Genetics Completes the Sale of Myriad myPath® Melanoma, LLC, Laboratory to Castle Biosciences

1 Jun 21

SALT LAKE CITY, June 01, 2021 (GLOBE NEWSWIRE) -- On May 28, 2021, Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in genetic testing and precision medicine, completed the sale of its wholly-owned subsidiary, Myriad

IPM Launches GeneSight® Pharmacogenomics Program for Depression and Anxiety

27 May 21

Myriad Genetics Signs Definitive Agreement to Sell Myriad RBM to Q2 Solutions

24 May 21

Investment data

Data from SEC filings

Securities sold

Number of investors

Calendar

5 May 21

24 Jun 21

31 Dec 21

Financial summary

Financial statements Chart MYGN financial data

Quarter (USD)	Mar 21	Sep 20	Jun 20	Mar 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Jun 20	Jun 19	Jun 18	Jun 17
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from company earnings reports.

Cash burn rate (estimated)	Burn method: Change in cash		Burn method: Operating income/loss		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	148.9M	148.9M	148.9M	148.9M	148.9M	148.9M
Cash burn (monthly)	(positive/no burn)	(positive/no burn)	16.53M	24.61M	(positive/no burn)	(positive/no burn)
Cash used (since last report)	n/a	n/a	46.09M	68.61M	n/a	n/a
Cash remaining	n/a	n/a	102.81M	80.29M	n/a	n/a
Runway (months of cash)	n/a	n/a	6.2	3.3	n/a	n/a

Beta Read what these cash burn values mean

Recent insider trades

MYGN insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
17 Jun 21	Spiegelman Daniel K	Common Stock	Sell	Dispose S	No	Yes	30.5176	3,139	95.79K	23,129
3 Jun 21	Heinrich Dreismann	Common Stock	Grant	Aquire A	No	No	0	12,848	0	83,527
3 Jun 21	Dennis Langer	Common Stock	Grant	Aquire A	No	No	0	12,848	0	89,527
3 Jun 21	Lee Nisley Newcomer	Common Stock	Grant	Aquire A	No	No	0	12,848	0	40,424
3 Jun 21	Spiegelman Daniel K	Common Stock	Grant	Aquire A	No	No	0	12,848	0	26,268

Data from 3, 4 and 5 filings. Stock values as filed, not updated for current price.

Institutional ownership Q1 2021

MYGN institutional ownership history Ownership history

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

99.6% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	194	187	+3.7%
Opened positions	37	25	+48.0%
Closed positions	30	26	+15.4%
Increased positions	53	58	-8.6%
Reduced positions	73	67	+9.0%

13F shares	Current	Prev Q	Change
Total value	3.51B	1.56B	+125.8%
Total shares	76.77M	78.66M	-2.4%
Total puts	83.4K	143.5K	-41.9%
Total calls	122.8K	173.2K	-29.1%
Total put/call ratio	0.7	0.8	-18.0%

Largest owners	Shares	Value	Change
BLK Blackrock	13.23M	$402.85M	+5.8%
Vanguard	8.62M	$262.62M	+4.0%
Earnest Partners	7.19M	$218.79M	+6.7%
STT State Street	4.03M	$122.86M	+8.6%
D. E. Shaw & Co	3.22M	$63.59M	0.0%
Camber Capital Management	3M	$91.35M	-40.0%
BAC Bank Of America	2.75M	$83.61M	+5.7%
Dimensional Fund Advisors	2.73M	$82.93M	-1.1%
Partner Fund Management	2.72M	$82.78M	NEW
D. E. Shaw & Co.	2.66M	$80.99M	-17.3%

Largest transactions	Shares	Bought/sold	Change
Partner Fund Management	2.72M	+2.72M	NEW
Camber Capital Management	3M	-2M	-40.0%
MS Morgan Stanley	746.4K	-1.48M	-66.4%
Glenview Capital Management	2.57M	-1.11M	-30.2%
Wellington Management	878.93K	+878.93K	NEW
Norges Bank	0	-731.26K	EXIT
BLK Blackrock	13.23M	+727.96K	+5.8%
D. E. Shaw & Co.	2.66M	-555.74K	-17.3%
IVZ Invesco	981.3K	+478.59K	+95.2%
Earnest Partners	7.19M	+453.92K	+6.7%

Data from 13F filings. Stock values as filed, not updated for current price. Long positions only.

Financial report summary

Competition

Aspira Women`s Health • Exact Sciences • Genomic Health • Exagen • Vyant Bio • Veracyte • Nanostring • Castle Biosciences • Invitae • Natera

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. sophomore Avg

New words: accurately, America, Autoimmune, behavior, capacity, cardiovascular, Castle, claim, clarification, combinatorial, Commonwealth, Conference, Delaware, Dermatology, diligently, disallowed, dollar, elevate, entertainment, established, expansion, explore, exploring, extension, fewer, formal, formally, found, founding, fully, Growth, immunoassay, inflammation, Intermountain, largest, leasehold, leave, Melanoma, misstatement, mix, multiplexed, myPath, newly, objectively, oncology, onset, play, primary, Psychotropic, purpose, RA, RBM, recovery, remediate, remediated, remediation, rheumatoid, robust, role, Score, select, sequencing, Society, somatic, specialty, submission, supervision, tumor, Zejula

Removed: adjustment, apply, applying, arrangement, authority, borrowed, breast, carried, categorized, classification, code, collected, commencement, comparative, concurrent, convertible, defined, determination, dismissed, Dividend, earliest, earned, efficiency, entry, fund, group, heading, highly, imposed, initially, jurisdiction, lack, large, liquid, model, October, Pathology, percent, perform, personal, pioneering, prospective, readily, realized, relationship, retrospective, scope, sheet, standing, subsequent, Supreme, upfront

From filing 10-Q 2021 Q1